Randomized controlled trials are the best way of testing therapeutic products to determine if they perform as expected and actually make a difference in treating a specific disease. Once preliminary evidence from phase II studies reveals that a treatment is probably effective, phase III trials are carried out to fully examine the risk/benefit profile of an experimental drug in a broader population over a longer period of time.
Titolo: | Time to abandon placebo control in pivotal phase III trials? |
Autori: | |
Data di pubblicazione: | 2015 |
Rivista: | |
Abstract: | Randomized controlled trials are the best way of testing therapeutic products to determine if they perform as expected and actually make a difference in treating a specific disease. Once preliminary evidence from phase II studies reveals that a treatment is probably effective, phase III trials are carried out to fully examine the risk/benefit profile of an experimental drug in a broader population over a longer period of time. |
Handle: | http://hdl.handle.net/11562/938560 |
Appare nelle tipologie: | 01.01 Articolo in Rivista |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.